AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Guanine deaminase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y2T3

UPID:

GUAD_HUMAN

Alternative names:

Guanine aminohydrolase; p51-nedasin

Alternative UPACC:

Q9Y2T3; B4DTY5; Q5SZC7; Q9H335; Q9ULG2

Background:

Guanine deaminase, also known as guanine aminohydrolase or p51-nedasin, plays a crucial role in nucleotide metabolism by catalyzing the hydrolytic deamination of guanine to produce xanthine and ammonia. This enzymatic process is vital for the catabolism of guanine, an essential purine base in DNA and RNA, into xanthine, which is further processed in the purine degradation pathway.

Therapeutic significance:

Understanding the role of Guanine deaminase could open doors to potential therapeutic strategies. Its pivotal function in purine metabolism suggests that modulation of its activity could have implications for disorders related to nucleotide imbalance or purine metabolism dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.